In adults at high CV risk and without previous MI or stroke, evolocumab reduced major adverse CV event composites at a median 4.6 y

Key Result

Evolocumab reduced major adverse cardiovascular event composites over a median 4.6 years in adults at high cardiovascular risk without prior MI or stroke.

Key Points

• The research aims to evaluate the effect of evolocumab on reducing major cardiovascular events in high-risk adults without prior myocardial infarction or stroke.
• Longitudinal study design focusing on adults at high cardiovascular risk
• Comparison of patients receiving evolocumab to those receiving standard care
• Follow-up duration of median 4.6 years
• Evolocumab significantly reduced the occurrence of major adverse cardiovascular events
• Reduction observed in composite of heart attacks, strokes, and cardiovascular-related deaths
• Patients without prior myocardial infarction or stroke experienced notable benefits